Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AstraZenecaAZN +3.03%77 EV-to-EBIT is 19.56 as of Aug. 20, 2026, which is 31% below its 10-year median of 28.20. GuruFocus rates AZN with a GF Score™ of 77/100 and a GF Value™ of $182.70 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 687 Drug Manufacturers companies, AstraZeneca ranks worse than 57.79% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
AstraZeneca's Enterprise Value for the quarter that ended in Jun. 2026 was $321,423 Mil.
AstraZeneca's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $14,332 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AstraZeneca EV-to-EBIT Related Terms
AstraZeneca EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for AstraZeneca's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, AstraZeneca's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AstraZeneca EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where AstraZeneca's EV-to-EBIT falls into.
AstraZeneca's current Enterprise Value is $280,306 Mil.
AstraZeneca's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $14,332 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AstraZeneca (AZN) has a EV-to-EBIT of 19.56 as of Aug. 20, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on AstraZeneca and its competitors. This is 31% below median its historical median of 28.20. According to the industry distribution chart, AstraZeneca ranks #397 out of 687 companies in the Drug Manufacturers industry, placing it in the top 57.8%.
Is AstraZeneca's EV-to-EBIT too high?
AstraZeneca's current EV-to-EBIT of 19.56 is 31% below median its 10-year median of 28.20. The Drug Manufacturers industry median EV-to-EBIT is 15.81. AstraZeneca's value of 19.56 is 23.7% above this industry median. Based on the distribution chart, AstraZeneca ranks #397 out of 687 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, AstraZeneca has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca's EV-to-EBIT compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, AstraZeneca ranks #397 out of 687 companies for EV-to-EBIT. This places AstraZeneca in the lower half of its industry. The industry median EV-to-EBIT is 15.81. AstraZeneca's value of 19.56 is 23.7% above this benchmark. While the company's 10-year median is 28.20 vs. the industry median of 15.81, AstraZeneca has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.81, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AstraZeneca's current EV-to-EBIT of 19.56 is 23.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on AstraZeneca and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AstraZeneca's current EV-to-EBIT is 19.56, which is 31% below median its own 10-year median of 28.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca (AZN) is currently considered Modestly Undervalued. The stock's GF Value™ is $182.70, compared to a current price of $164.95 — trading 9.7% below its estimated fair value. The current EV-to-EBIT is 19.56, which is 31% below median its 10-year median of 28.20 and 23.7% above the Drug Manufacturers industry median of 15.81. AstraZeneca's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For AstraZeneca (AZN), the current EV-to-EBIT is 19.56 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AstraZeneca (AZN) Overvalued in 2026?
Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued.
The current stock price of $164.95 is trading 9.7% below its estimated GF Value™ of $182.70.
GuruFocus considers AstraZeneca to be Modestly Undervalued.
Key valuation signals for AZN:
EV-to-EBIT: 19.56 (31% below median its 10-year median of 28.20)
GF Value™: $182.70 vs. price of $164.95 (9.7% below fair value)
Industry Position: 23.7% above the Drug Manufacturers median (#397 of 687)
No single metric tells the full story. See the AZN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
77GF Score
Get the complete analysis for AZN
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AZN has been successfully added to your 
